Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous N-acetylcysteine for respiratory diseases with abnormal mucus in China
NCT03843541Phase 3Completed
- Sponsor
- Zambon
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in Respiratory tract disease (RTD) (3 arms), sponsored by Zambon. Primary endpoints: Change From Baseline to Day 7 of Mean Sputum Viscosity Score and Change From Baseline to Day 7 of Mean Expectoration Difficulty Score. Started Jun 2019; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Respiratory tract disease (RTD)
Beyond the preview
Go deeper on NCT03843541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843541.